Site Search :
查查英汉在线翻译
Newsmore
·Fifth Ministerial Conference of Forum on China-Africa Cooperation Held in Beijing
·Drug Fight Confronted with More Challenges
·Senior CPC Leader Returns to Beijing after Four-country Visit
Culturemore
·Calligraphy, Then and Now
·Lotus Painter Cai Qibao
·The Olympic Ideal
Tourismmore
·Riverside Romance in Central Anhui
·Into the Wild – Hiking through Qizang Valley
·Folklore Flying High in Weifang
Economymore
·China’s Soft Power: Room for Improvement
·Browse, Click, Buy - Domestic Consumers Head Overseas with Online Shopping
·A Private Company’s Road to Internationalization
Lifemore
·Zhang Jiao, Ardent Advocate of Afforestation and Green Farming
·First Single Children Come of Age
·E-Government: Open, Approachable Government Websites
Around Chinamore
·Scientists Uncover Causes of Mass Extinction in the Ashes
·Kaili -- Scenery, Music and Southern Charm
·Ningxia: Putting Money Down on Culture
News  

Gastric Cancer Breakthrough

    China has developed the world's first oral vaccine for Helicobacter pylori (HP), a bacterium closely linked to gastric cancer. The vaccine is designed to prevent infection by HP that inhabits parts of the stomach, believed to be strongly linked to the development of duodenal and gastric ulcers and even stomach cancer.

    This is the world's first HP vaccine to finish large-scale phase-three clinical trials and become ratified as a new medicine. The vaccine has been classified as a "first-grade new medicine" by the State Food and Drug Administration, China's drug watchdog.

    It was developed by a research team from the Chongqing-based Third Military Medical University. During the research process, the vaccine secured eight national patents and now has full independent intellectual property rights. Clinical research shows that the vaccine has a protection rate of more than 72.1 percent against HP.

VOL.59 NO.12 December 2010 Advertise on Site Contact Us